Apogee Therapeutics, Inc. Common Stock Total Liabilities
Apogee Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has total liabilities worth $141.21 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See APGE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Apogee Therapeutics, Inc. Common Stock (2022–2025)
Total liabilities of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Apogee Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check APGE financial resilience to evaluate the company's liquid asset resilience ratio.
Apogee Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Lottery Corporation Ltd
AU:TLC
|
Australia | AU$5.19 Billion |
|
ALIB.HL.INF.TEC.UNSP.ADR
F:TWYA
|
Germany | €5.70 Billion |
|
Match Group Inc
NASDAQ:MTCH
|
USA | $4.63 Billion |
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
Taiwan | NT$2.23 Trillion |
|
National Silicon Industry Group Co Ltd
SHG:688126
|
China | CN¥14.36 Billion |
|
Ayvens SA
PA:AYV
|
France | €60.09 Billion |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
Greece | €72.38 Billion |
|
NHPC Limited
NSE:NHPC
|
India | Rs645.23 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Apogee Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Apogee Therapeutics, Inc. Common Stock asset portfolio.
Liquidity & Leverage Metrics
Apogee Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Apogee Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apogee Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.25 Million | -10.51% |
| 2024-12-31 | $37.16 Million | +72.90% |
| 2023-12-31 | $21.49 Million | +115.34% |
| 2022-12-31 | $9.98 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chr… Read more